Study on the prevalence of human T-cell lymphotropic virus among blood donors in Guangdong

doi:10.19871/j.cnki.xfcrbzz.2022.04.004

Abstract

Abstract: Objective Investigate the prevalence of human T-cell lymphotropic virus (HTLV) among blood donors in Guangdong province, so as to improve blood safety and provide support for health authorities to formulate blood screening policies. Method Enzyme linked immunosorbent assay (ELISA) was used to conduct preliminary screening on blood donors in the whole province from January 2018 to October 2021. Those who failed to pass the test were recorded as positive in preliminary screening and further confirmed by Western blotting (WB). A positive result of confirmation test was considered to be HTLV positive. According to the results of the confirmatory test, the prevalence of HTLV in Guangdong province and each city was figured out, then regional and interannual variations in prevalence rate were analyzed. Result A total of 4 702 539 blood donors were screened in Guangdong province in four years. Therein, 1427 blood donors were found to be positive in ELISA but only 74 blood donors were confirmed positive for HTLV, with a prevalence rate of 0.0016% (74/4 702 539). The prevalence of HTLV in eastern Guangdong is higher than that in northern Guangdong, western Guangdong and the Pearl River Delta (χ²=5.567, P=0.02; χ²=13.502, P<0.001; χ²=32.612, P<0.001). Shanwei in eastern Guangdong had the highest prevalence rate of HTLV in the province (7/56 691, 0.0123%).The prevalence rates of HTLV in the four years were 0.0018% in 2018, 0.0012% in 2019, 0.0016% in 2020 and 0.0018% in 2021, respectively. The difference was not statistically significant (χ²=1.965, P=0.58). Conclusion Guangdong is a low epidemic area of HTLV. In order to improve the quality of blood products, it is suggested to carry out HTLV screening in areas with high prevalence. As for other regions, flexible strategies can be adopted according to the local economic development.

Key words: Human T-cell lymphotropic virus, Prevalence rate, Blood donors, Guangdong province

Zhong Huishan, Shan Zhengang, Liao Qiao, Xu Ru, Huang Jieting, Wang Min, Rong Xia. Study on the prevalence of human T-cell lymphotropic virus among blood donors in Guangdong[J]. Electronic Journal of Emerging Infectious Diseases, 2022, 7(4): 16-19.

References

[1] POIESZ BJ, RUSCETTI FW, GAZDAR AF, et al.Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma[J]. Proc Natl Acad Sci USA, 1980, 77(12): 7415-7419.
[2] SHIMOTOHNO K, TAKAHASHI Y, SHIMIZU N, et al.Complete nucleotide sequence of an infectious clone of human T-cell leukemia virus type II: an open reading frame for the protease gene[J]. Proc Natl Acad Sci USA, 1985, 82(10): 3101-3105.
[3] TAGAYA Y, MATSUOKA M, GALLO R.40 years of the human T-cell leukemia virus: past, present, and future[J]. F1000Res, 2019, 8:F1000.
[4] DE ALCANTARA MANESCHY C, DOS SANTOS BARILE KA, DE CASTRO JAA, et al. Epidemiological and molecular profile of blood donors infected with HTLV-1/2 in the state of Para, northern Brazil[J]. Braz J Microbiol, 2021, 52(4): 2001-2006.
[5] GESSAIN A, CASSAR O.Epidemiological Aspects and World Distribution of HTLV-1 Infection[J]. Front Microbiol, 2012, 3:388.
[6] GROSS C, THOMA-KRESS AK.Molecular Mechanisms of HTLV-1 Cell-to-Cell Transmission[J]. Viruses, 2016, 8(3): 74.
[7] DU J, CHEN C, GAO J, et al.History and update of HTLV infection in China[J]. Virus Res, 2014, 191:134-137.
[8] 陈长荣, 谢金镇, 张永昌, 等. 厦门市无偿献血者HTLV感染情况及基因亚型分析[J]. 中国输血杂志, 2012, 25(12): 1257-1261.
[9] 刘忠, 李玲. HTLV与血液安全[J]. 中国输血杂志, 2017, 30(3): 221-223.
[10] 张春涛. 人T细胞白血病病毒Ⅰ型的研究现状[J]. 微生物学免疫学进展, 2003, 31(2): 57-61.
[11] SATAKE M, YAMAGUCHI K, TADOKORO K.Current prevalence of HTLV-1 in Japan as determined by screening of blood donors[J]. J Med Virol, 2012, 84(2): 327-335.
[12] KWON SY, LIM AH, PARK JY, et al.Seroprevalence of human T-lymphotropic virus type 1 and 2 in Korean blood donors[J]. J Med Virol, 2008, 80(10): 1864-1867.
[13] LU SC, CHEN BH.Seroindeterminate HTLV-1 prevalence and characteristics in blood donors in Taiwan[J]. Int J Hematol, 2003, 77(4): 412-413.
[14] NAMEN-LOPES MS, MARTINS ML, DRUMMOND PC, et al.Lookback study of HTLV-1 and 2 seropositive donors and their recipients in Belo Horizonte, Brazil[J]. Transfus Med, 2009, 19(4): 180-188.
[15] BERINI CA, GENDLER SA, PASCUCCIO S, et al.Decreasing trends in HTLV-1/2 but stable HIV-1 infection among replacement donors in Argentina[J]. J Med Virol, 2010, 82(5): 873-877.
[16] DORSEY KA, MORITZ ED, STEELE WR, et al.A comparison of human immunodeficiency virus, hepatitis C virus, hepatitis B virus, and human T-lymphotropic virus marker rates for directed versus volunteer blood donations to the American Red Cross during 2005 to 2010[J]. Transfusion, 2013, 53(6): 1250-1256.
[17] DAVISON KL, DOW B, BARBARA JA, et al.The introduction of anti-HTLV testing of blood donations and the risk of transfusion-transmitted HTLV, UK: 2002-2006[J]. Transfus Med, 2009, 19(1): 24-34.
[18] 欧山海, 林洪铿, 徐冬峰, 等. 福建省无偿献血者HTLV-1/2感染情况研究[J]. 中国输血杂志, 2020, 33(6): 610-613.
[19] 张婧, 王瑞, 胡京辉, 等. 基于大标本量基础分析北京地区献血人群HTLV-Ⅰ/Ⅱ感染情况[J]. 中国输血杂志, 2020, 33(8): 814-817.
[20] 励晓涛, 董杰, 凌霞, 等. 浙江省无偿献血人群抗HTLV感染状况分析[J]. 中国现代医生, 2022, 60(3): 162-164.
[21] 陈慧, 冯涛, 朱绍汶, 等. 2016-2019年江苏地区无偿献血人群HTLV-I/II流行情况调查[J]. 中国实验血液学杂志, 2021, 29(4): 1308-1311.
[22] 熊丽红, 胥四新. 江西省无偿献血者HTLV感染情况调查[J]. 实验与检验医学, 2017, 35(6): 860-861.
[23] 张文静, 刘金玲, 陈元锋, 等. 山东省58395例献血者中人类嗜T淋巴细胞病毒感染的检测[J]. 临床输血与检验, 2018, 20(5): 476-478.
[24] 林杰, 黄国永, 刘燕飞, 等. 温州地区无偿献血者人类嗜T淋巴细胞白血病病毒感染情况分析[J]. 中国输血杂志, 2017, 30(7): 794-795.
[25] 董杰, 励晓涛, 凌霞, 等. 杭州无偿献血人群人类嗜T细胞白血病病毒流行概况[J]. 国际流行病学传染病学杂志, 2019, (5): 366-369.
[26] VOSE J, ARMITAGE J, WEISENBURGER D, et al.International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes[J]. J Clin Oncol, 2008, 26(25): 4124-4130.